The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'd pxxs myself laughing if I got my £30k back from this... would be such a laugh... only needs to go to 20p..
Lambo222 - you totally misinterpreted IMM's radio silence as a sign a dilutive fundraise was imminent.
Now I fear you're also misinterpreting today's RNS as a sign"partner deals clearly very close".
There are NO guarantees any partner deals are close. However, there IS clarity IMM has sufficient cash for now, having slashed its overheads & acquired warrants & a near 11% holding in Incanthera.
Incanthera finally seems to be going places, following the announcement of its commercial deal with Marionnaud, an A S Watson subsidiary.
So yes, this news IS positive for IMM in the short to medium term. Just not for the reason you give.
Brilliant interview but heard the positives before again saying they will keep up with shareholders better communication. Said should be couple deals done this year. Will wait and see would love him to prove the past dissapointment is in past so give him till end of year
My average is 28p, so still a long , long way to recovery... If it survives til then.
I’m still down 95%,
‘Strong message to market - No dilution’
The Devils Advocate in my experienced past also dictates a little caution. The RNS also provided Lanstead with a perfect route to sell more shares. Call me sceptical - still waiting and watching for some new news.
Don’t fool for this, excuse the pun
With that RNS, one could expect that some contract will be signed in the very near future..
Tim has Always done the talk but he should know by now that actions speak louder than words..
The Next update should be very informative, imo
Let's wait and see
Which account?
Absolutely correct Scrodingerscat, not one word from that account can be used for information or opinion.
Lambo222 I will give you credit for saying you were wrong. However that doesn't absolve of you of your sins, read back over your posts before you start ramping again. A character without shame.
" & A Promise of No Further Dilution! "
nothing of the sort..no promises given ....
totally misleading to say so....
Flash212 - you say "nothing new in todays update apart from saying we are not going bust".
For now, that in itself dispels a HUGE cloud that was hovering over investors' minds.
I also think you've (deliberately?) ignored the clarification on significantly reduced overheads & the value of IMM's shareholding & warrants in Incanthera, which are exercisable any time.
Before today, the biggest worry was that IMM would simply run out of cash before it could monetise any of its drug developments.
After today, that fear has - at least in the short to medium term - disappeared.
If that’s the best they can do, it really sums them up.
Maybe I’m whistling in the wind
Same price as 3 weeks ago. Hardly a resounding vote of confidence from the market.
Things will turn in a month or so and they’ll raise.
Wishy washy as usual from this nothing company. No product. No revenues.
Writing on the wall, DYOR
So, Dallo, myself and others having contacted IMM are pleased to see this re-statement of the fundamentals. The prescence of Dr Reilly encourages me to think that much of this will happen. I cannot understand the poster who says that nothing has happened given the deal worth $25m to fund LUPUS for the US market-that is something that is happening. Also the deal for INC with Watsons.
I hope IMM realise that regular updates with help the confidence of ling term shareholders.
GLA
Company in active discussions with a broad range of potential commercial partners with the objective of completing deals across the portfolio in 2024
Untapped value with its 10.8% holding in Incanthera worth £916000
‘Board is positive about short, medium and long term future’
Going to make a coffee and read it all again
" staggering reduction of operational costs...This remarkable achievement "
you are having a laugh .... they should have done it well before they did....and most of it was staring them in the face ...
Dear long-term Shareholders,
As someone deeply invested in ImmuPharma, with a substantial holding of 9 million shares, I am eager to express my enthusiasm for our company's recent landmark announcement. This update isn't just news; it's a testament to the strategic foresight and unwavering commitment of our team.
Robust Financial Footing & A Promise of No Further Dilution
We've reached a pivotal moment where ImmuPharma's financial health is stronger than ever, confirmed by our strategic avoidance of equity fundraising in the near term. Our financial prudence, combined with active engagements to secure non-dilutive income from our rich asset portfolio, including P140 for Lupus and BioAMB, signifies a future ripe with opportunity and growth.
Operational Excellence: Streamlined for Success
A staggering reduction of operational costs by over 75% reflects the commitment to lean and focused operations. This remarkable achievement has not only optimised the resource allocation but also underscores the capability to direct our energies toward pivotal projects. ImmuPharma now operates with unparalleled efficiency, setting a new standard in the biotech industry.
Strategic Alliances: Broadening Horizons with Avion
Our collaboration with Avion and ongoing discussions for Lupuzor's non-US rights showcase the power of strategic partnerships. Avion's support and the anticipated updates on this collaboration promise to catapult us into new realms of possibility and success.
Pioneering Developments: P140 & Beyond
The advancements in our P140 Lupuzor Phase 3 study, led with precision by Simbec-Orion, underscore its groundbreaking potential. This, along with the CIDP program's momentum, illuminates our path towards revolutionising autoimmune disease treatment.
Incanthera Investment: A Goldmine Awaiting Unveil
Our stake in Incanthera has proven to be a strategic masterstroke. With Incanthera's trajectory set for a spectacular year, marked by their recent triumphs detailed in their RNS announcements, we stand on the cusp of realising significant gains from this investment.
A Note of Appreciation and A Call to Vision
A massive thanks goes to Tim McCarthy, Lisa Baderoon, and the entire ImmuPharma team for steering our ship with courage and foresight. Their relentless pursuit of excellence has not only weathered storms but also prepared us for a dawn filled with success and prosperity.
In closing, ImmuPharma isn't just navigating the present; we're crafting a future where our strategic decisions today will forge a legacy of innovation and success. My confidence in our journey forward is unshaken, and I eagerly anticipate the unfolding of our collective aspirations.
IImmuPharma is not a haven for the short-sighted or the ill-informed seeking quick gains. It's a realm for the sophisticated investor, for those with clever vision and knowledge, who recognise the untapped value of this hidden gem.
This letter offers personal i
"Wait for the brutal RNS. Writing on the wall since the turn of the year. DYOR".
OBVIOUSLY HE MISSED HIS OWN ADVICE AND DID NOT DO HIS OWN RESEARCH. THEN PERHAPS HE DID. and it was flawed. Anyone seen the moneymule today?
And not a word or peep out of Nobinpis.
Just hold, we can and will push this over the finish line.
Frits
Mrbrain
I suspect the NOMAD required this point about "no guarantee"
"Whilst there can be no guarantee of completing commercial deals, there are a broad range of discussions currently taking place and the objective is to complete deal(s) across the portfolio in 2024.
All very true though worth adding that the NOMAD would have had to have seen something to justify the expectations being put in an RNS, e.g. the nature and current state of partnership discussions.